Your fact-checks will appear here
British multinational pharmaceutical and biotechnology company
The 2025–2026 Northern Hemisphere flu vaccines are trivalent and chosen to target one H1N1 A strain, one H3N2 A strain, and one B/Victoria-lineage strain; U.S. regulators (FDA/CDC) recommended these c...
This season's influenza vaccines for 2025–2026 are not described in the cited reporting as being based on ; public health agencies and manufacturers list egg‑based, cell‑culture, recombinant protein, ...
Three distinct RSV vaccines authorized in recent years use different active ingredients: protein-based “prefusion F” antigens in Pfizer’s ABRYSVO and GSK’s AREXVY, and a nucleoside‑modified mRNA encod...
The currently recommends a single dose of an for all adults age 75 years and older, and for adults ages 50–74 who are at increased risk for ; earlier guidance and professional groups also noted recomm...
Two widely discussed squalene-containing adjuvants used with influenza vaccines are MF59 and AS03; MF59 is the adjuvant in Fluad, an FDA‑licensed vaccine for adults ≥65, while AS03 and AF03 are other ...
Bill Gates has made personal investments aimed at Alzheimer’s research totaling about $100 million — a $50 million check to the Dementia Discovery Fund (DDF) and roughly $50 million pledged for start‑...
, the recombinant zoster vaccine introduced as a more effective successor to Zostavax, has provoked debate largely centered on rare but serious neurologic events, higher reactogenicity than older vacc...
Post-licensure monitoring of has flagged a handful of rare but serious adverse-event signals — notably (GBS), and thrombocytopenia, atrial fibrillation/cardiac events, in pregnancy, and a safety signa...
The pivotal phase 3 ZOE-50 and ZOE-70 trials that supported SHINGRIX licensing were randomized, observer‑blind, placebo‑controlled studies — participants were assigned to receive two doses of the reco...
The Advisory Committee on Immunization Practices (ACIP) voted 8–3 to remove the long-standing universal newborn hepatitis B (Hep B) birth‑dose recommendation, shifting to individual/shared decision‑ma...
Major vaccine-makers show wide variation in margins driven by product mix (high-margin biologics/vaccines vs. pandemic-era COVID shots), inventory charges and one‑off items: Pfizer’s recent adjusted o...
Manufacturer copay cards frequently apply to brand-name inhalers to lower out‑of‑pocket costs for commercially insured and uninsured patients, but those savings programs generally exclude people with ...
Pfizer told lawmakers and the public that its decisions and communications about COVID‑19 vaccine timing were “driven by science and guided by the U.S.” regulatory process, saying it would respond to ...
For the 2025–2026 U.S. influenza season, federal guidance and product labeling show a clear shift to single‑dose, thimerosal‑free presentations: ACIP and CDC recommend that vaccines for children, preg...
There is no evidence in the provided reporting that any regulator‑approved supplement can modify the biological progression of frontotemporal dementia (FTD); multiple clinical reviews and advocacy gro...
There is no reporting in the documents provided that says Donald Trump personally invested capital into pharmaceutical companies or pharmaceutical-focused investment funds; the available sources descr...
For the 2025–26 U.S. season, most manufacturers are supplying single‑dose, thimerosal‑free prefilled syringes — specifically GSK’s Fluarix and Flulaval, Seqirus’s Afluria and Fluad, and CSL Seqirus’s ...
Available sources identify David E. Martin as a business founder and executive with a doctorate who built a career in patent analytics, drug development and corporate consulting rather than as a tradi...
have become a common route for large drug companies to hand off decisions about who gets patient‑level clinical trial data: has formalized that transfer with the YODA Project and also lists YODA as a ...
A substantial subset of large pharmaceutical firms have formal policies or platforms that permit of de‑identified participant‑level data (PLD), but access is heterogeneous, conditional, and often medi...